PET is an important functional imaging technique that can be used to investigate neurotransmitter receptors and transporters directly by mapping human brain function. PET is increasingly being used greatly to advance our understanding of the neurobiology and pathophysiology of schizophrenia. Methods: This review focuses on the use of PET tracers and kinetic modeling in identifying regional brain abnormalities and regions associated with cognitive functioning in schizophrenia. A variety of PET tracers have been used to identify brain abnormalities, including 11 C, 15 O-water, 18 F-fallypride, and L-3,4-dihydroxy-6-18 F-fluorophenylalanine ( 18 F-FDOPA). Results: Some studies have used compartmental modeling to determine tracer binding kinetics. The most consistent findings show a difference in the dopamine content in the prefrontal cortex, anterior cingulate gyrus, and hippocampus between healthy controls and patients with schizophrenia. Studies also show a higher density of D 2 receptors in the striatum and neural brain dysconnectivity. Conclusion: Future investigations integrating clinical, imaging, genetic, and cognitive aspects are warranted to gain a better understanding of the pathophysiology of this disorder.
suggested that this is more likely a result of presynaptic dysregulation than increased dopamine receptors. PET and SPECT use tracers that specifically bind to receptors that can be used to measure changes in receptor occupancy.
PET has provided useful insights into the pathophysiology of schizophrenia that have recently led to an upsurge in research interest. We introduce briefly the concept and basic principles of PET. Studying dopaminergic imbalances in schizophrenia requires an in-depth insight into other associated factors. We therefore provide an overview on schizophrenia. This background will prove useful as a basis for understanding subsequent sections, which discuss the use of PET to identify regional brain abnormalities in schizophrenia. We provide an integrative review of the leading ideas that use PET to detect neural activity and changes in cognitive activation paradigms.
PRINCIPLES OF PET/CT
PET facilitates the assessment of cerebral metabolic activity and blood flow and identifies the activation of dopaminergic pathways using specific tracers and neurotransmitter receptor function. These tracers emit positrons that interact with nearby electrons, producing g-photons that are detected by scintillation crystals in the scanner, producing an image of tracer uptake.
Dopamine receptor function studies involve the injection of a radiolabeled tracer having high affinity and specificity for a specific receptor. Quantification is based on the amount of receptor binding over time. This technique can also be used to observe the effects of drugs on the binding efficiency of brain dopamine receptors. The data can also be used to determine the degree of receptor occupancy and drug uptake time, which may help determine the optimum dose. It is also possible to create a detailed map of motor function or cognitive processes of the brain while an individual is undergoing a cognitive task ''online.''
OVERVIEW OF SCHIZOPHRENIA
Schizophrenia is a severe and complex brain disorder. The lifetime prevalence is around 1.4-4.6 per 1,000 and the annual incidence between 0.16 and 0.42 per 1,000 (9) . It afflicts almost 1% of the world's population, is the seventh most costly medical illness in our society (10) , and ranks ninth in global burden of illness (11, 12) . Schizophrenia typically has an onset in late adolescence or early adulthood and is characterized by positive and negative symptomatology together with defects of psychosocial and cognitive functioning (13) . The clinical diagnosis is based on the DSM-IV-TR of the American Psychiatric Association (14) , which requires patients to present with core symptoms for at least 1 month.
Symptoms vary over the course of the illness but broadly fall into 4 phases (premorbid, prodromal, residual, and active). The prodromal and residual phase symptoms are relatively mild forms of the active phase (Fig. 1) .
Cognitive Deficits
Cognitive dysfunction is a recognized feature in schizophrenia. Patients perform 1.5-2.0 SDs below the normative mean of healthy age-matched individuals (15) , with differential impairment in verbal learning and memory function up to 3 SDs (16) (17) (18) . Neurocognitive deficits occur independently of antipsychotic treatment (17) and are not necessarily associated with psychotic symptoms (19, 20) . Cognitive deficits appear to be a primary predictor of functional outcome (21, 22) . Cognitive impairments are relatively stable across all domains (23) and do not fluctuate in accordance with clinical symptom change (16) .
Neurodevelopmental and Genetic Influences
The original neurodevelopmental model proposed that disruptions in the central nervous system during ontological development (second or third trimester) interact with normal brain maturational events and may result in structural brain abnormalities that cause symptomatology (24) . Recent formulations have integrated biological and environmental factors that may influence brain development during adolescence (25, 26) . Schizophrenia has a strong genetic predisposition, with heritability estimates of approximately 80% (27, 28) .
It is well established that schizophrenia has a multifactorial basis whereby the additive actions of several genes of small effect combined with the effects of noninherited factors (environmental risk indicators) contribute to increased liability to the disorder (29) . Several genes associated with schizophrenia seem to have a functional role over the life span (27) . Evidence from linkage studies favors disrupted-in-schizophrenia-1 (30, 31) , neuregulin-1 (32, 33) , and dysbindin (34, 35) as the most promising candidate genes for schizophrenia (36) . Some neurochemical genes associated with dopamine regulation, such as the catechol-O-methyltransferase (COMT) gene (37, 38) , have been associated with performance during prefrontal-mediated working memory tasks (39) (40) (41) (42) (43) . Several genes are involved in other neurotransmitter pathways. More recently, technologic advances have shown that copy-number variants (CNVs) could be important in disease pathogenesis (44) . CNVs are DNA segments (.1 kilobase) that are at the rare (e.g., 1/500 patients) end of the disease spectrum and are commonly a duplication or deletion with frequencies of more than 1%. Two CNVs have been found to be associated with increased risk: deletions at 1q21.1 and 15q13.3 (45) . Higher burdens of deletions have been identified in childhood-onset schizophrenia (20%) than in adult-onset cases (15%) and healthy controls (5%) (45) . Evidence suggests that several CNVs may be linked with increased susceptibility to schizophrenia. There is urgency for the replication of such findings to strengthen the evidence for the association with CNVs and schizophrenia.
NEUROCHEMICAL FINDINGS

Dopamine Hypothesis
The reformulated dopamine hypothesis suggested that striatal hypodopaminergia was associated with negative symptoms and striatal hyperdopaminergia with positive symptoms, such as hallucinations and delusions, and antipsychotic treatment response (24, 46) . The hypothesis was driven by the discovery that all typical antipsychotic medications are dopamine receptor antagonists and that amphetamines (known dopamine-releasing agents) can induce paranoid psychotic features. Volkow et al. (47) reviewed the dopamine hypothesis.
A further revision of the dopamine hypothesis, based on findings stemming from imaging studies identifying brain anatomic and connectivity abnormalities, cognitive impairments, molecular genetics, and the influence of environmental risk factors, has provided vital insights into the dopamine pathways (48) . Positive symptoms are considered to be a result of the increased subcortical release of dopamine causing greater stimulation of D 2 receptors (D 2 Rs); therefore, the primary target of many antipsychotic drugs is antagonism at striatal D 2 Rs. Cognitive deficits and negative symptoms are resistant to treatment by most typical antipsychotic drugs and arise from reduced D 1 receptor (D 1 R) stimulation (49) . The distribution of D 2 Rs in specific brain regions has been noted ( Fig. 2) Kapur (8) proposed that increased dopaminergic neurotransmission is a state of dysfunction associated with positive symptomatology and suggested that during the late adolescence period patients develop abnormalities in the formation of the dopamine system that do not synchronize with normal stimuli and lead to an exaggerated release of dopamine. This has been supported by other groups (54, 55) .
Abi-Dargham et al. (3) measured striatal D 2 Rs with a D 2 R antagonist in 18 untreated patients and 18 controls. Previously, no difference has been seen between these 2 groups. Differences were apparent only when the participants were depleted of dopamine by 75%. The study suggests that patients with schizophrenia have a greater occupancy, and presumably simulation of D 2 Rs by dopamine, with patients having the most overactive dopamine system responding best to drugs. The low concentration of D 2 Rs in extrastriatal regions has limited the use of PET in D 2 measurement.
To extend the dopamine hypothesis, Kapur et al. (56) combined the biological role of dopamine and a theory on motivational salience, whereby apparently neutral events or stimuli grab the attention because of their association with rewards and aversions (reinforcement), leading to goalspecific behavior because of striatal dopamine release (57, 58) . Therefore, increased dopamine release, which occurs in acute psychosis (3), leads to the assignment of increased attention and excessive reinforcement (or salience) to relatively innocuous stimuli. Delusions are then an attempt to resolve the imbued conflicting and confused state of mind (59) . In the context of the development of the full-blown illness, dopamine is ''the wind of the psychotic fire'' (60). Dopamine transmission is important in cognitive performance. Severe spatial working memory impairments result from prefrontal cortical dopamine depletion cortex (61). Arnsten (62) suggested an inverted-U curve relationship of D 1 R activation and prefrontal function, whereby excessive or insufficient dopamine levels are associated with impaired working memory performance. The administration of a D 1 R agonist improves performance in rats that initially showed poor attentional ability, whereas no amelioration occurs in rats with good performance (63) . The administration of a D 2 R agonist improves cognitive abilities in humans with low basal memory but shows impairments in performance in individuals with high basal memory capacity (64) . A possible explanation for changes associated with dopaminergic hypofunction or hyperfunction may be offered by the finding that those with COMT Val158 homozygosity demonstrate suboptimal prefrontal cortex (PFC) dopamine activity, whereas COMT Met158 homozygotes show an intermediate PFC dopamine state. Amphetamine treatment differentially affects the COMT Val158Met gene, whereby Val158 homozygotes show improved performance on PFC-related cognitive tasks and thus PFC efficiency. Met158 homozygotes, however, show impairments in PFC function resulting from superoptimal dopamine levels (65) . Thus, prefrontal function, dopamine D 1 activation, and basal activity are related (66, 67) .
Subsequent PET studies have shown that schizophrenia is associated with heightened presynaptic striatal dopamine synthesis and storage (68, 69) . The administration of amphetaminelike drugs causes an increase in striatal dopamine in schizophrenia (70, 71) , leading to a change in the specific binding of the D 2 /D 3 PET ligand in drug-free and drugnaïve patients but only when patients are acutely symptomatic and not during remission. D 2 R densities are increased in schizophrenia, but antipsychotic treatment is a confounder (72). Serotonin (5-HT) is a neurotransmitter that occupies a unique place in neurobiology because of its role in several physiologic processes. Serotonin has been implicated in a wide range of central nervous system functions including sleep, pain reception, sexual behavior, thermoregulation, hormone secretion, appetite, and cognitive function and the modulation of responses to stress and anxiety.
Over half a century ago, the biochemists Dilworth Wayne Woolley and Elliott Shaw, who had performed seminal work on serotonin (also known as enteramine at that time), suggested that on the basis of infra-human animal laboratory studies changes in central serotonergic pathways were likely to be germane to schizophrenia and that, therefore, serotonergic pharmacologic human trials in schizophrenia were indicated (73) . In addition, serotonin was initially considered to be important in schizophrenia because of the effects of atypical antipsychotics on serotonin receptors and the psychotogenic effects of LSD. Postmortem human studies have demonstrated decreased cortical 5-HT 2A R in schizophrenia, although to date there are no converging data to support a particular allelic variant of this receptor as being etiologic (74) . Using single-point saturation analyses to estimate the total number of 3 Hketanserin binding sites in tissue sections, Dean et al. have recently found evidence consistent with the hypothesis that apparent decreases in 5-HT 2A R in schizophrenia are the result of altered levels of a regulatory factor (or factors) that modulates the binding of ligands to the 5-HT 2A R; separating the membrane and cytosol removes this regulatory control (75) . Furthermore, a significant interaction has been reported in schizophrenia between the Val66Met brainderived neurotrophic factor and 5-HT 2A R T102C polymorphisms and visual attention (76) . On the basis of this evidence, and given the availability of suitably selective radioligands, it is clearly apposite to perform 5-HT 2A PET studies in this illness (4,6). 5-HT 2A R PET radiotracers with appropriate in vivo properties include 18 F-setoperone (77), 18 F-altanserin (78) , and 11 C-MDL 100 907 (79) (82) have criticized these studies on the grounds that the predefined regions of interest (ROIs) were observer-dependent, with much of the brain left unexplored; these authors performed a similar study, with the data being analyzed on a voxel-by-voxel basis, the 5-HT 2A R binding potential being determined for each voxel using the pseudoequilibrium ratio method on PET data obtained 65-90 min after the radiotracer bolus injection. Again, no significant between-group differences were found. Furthermore, no significant correlations were observed between any of 5 factors (negative, positive, activation, dysphoric, and autistic preoccupation) derived from the positive and negative syndrome scale for typologic and dimensional assessment (83) and 5-HT 2A R binding potential (82) . However, using 18 F-setoperone PET to study 6 antipsychotic-naïve schizophrenia patients and 7 healthy controls, Ngan et al. (84) 18 F-setoperone was found in the chlorpromazine group; for the highest dose, there was a virtual lack of sites available for binding. A low percentage of available binding sites was also found in the clozapine-treated patients at all doses; no significant binding of amisulpride was detected. These findings suggest a high level of 5-HT 2A blockade with both the archetypal atypical antipsychotic clozapine and the high doses of the archetypal typical antipsychotic chlorpromazine (85) . Although amisulpride has no 5-HT2A blockage efficacy, it is still an effective antipsychotic medication. To study the binding characteristics of the atypical antipsychotic quetiapine, patients were treated with different quetiapine doses and 11 C-raclopride and 11 C-N-methylspiperone PET used to study cortical D 2 and 5HT 2A occupancies, respectively (86); a pattern of high 5HT 2A R and lower D 2 R blockade occurred. Similarly, an 11 C-raclopride and 18 F-setoperone PET study of the atypical antipsychotic ziprasidone in schizophrenia or schizoaffective patients showed greater 5HT 2A R than D 2 R occupancy at therapeutic doses (87) . PET has been used to examine other serotonin receptors (such as 5HT 1A ) (88) and transporters (89) .
PET IN IDENTIFICATION OF REGIONAL BRAIN ABNORMALITIES IN SCHIZOPHRENIA Use of Imaging
A variety of PET tracers has been used to identify brain abnormalities.
11 C Studies. The PFC and striatum play an important role in schizophrenia (51 11 C PET to map D 1 /D 2 receptors in the human brain. They found no differences in the striatum in schizophrenia patients, compared with control subjects, but reduced prefrontal cortical D 1 R signaling was observed in those with schizophrenia. Lindström et al. (7) reported heightened dopamine synthesis in the medial PFC and striatum in patients with schizophrenia, compared with controls (Fig.  3) . A recent metaanalysis showed a small but significantly heightened level of striatal D 2 Rs in unmedicated patients (91) .
18 F-Fallypride Studies. 18 F-fallypride or 11 C-fallypride is a dopamine receptor ligand with high affinity and specificity (92) . PET 11 C studies show a decline in D 1 R binding potential of 7%29% per decade in the putamen, caudate nucleus, frontal cortex, and occipital cortex (93).
Buchsbaum et al. (94) coregistered 18 F-fallypride PET and MRI in drug-naïve schizophrenia and matched controls. Schizophrenia was associated with reduced extrastriatal D 2 R/D 3 R availability in the thalamus, amygdala, cingulate gyrus, and temporal cortex, with the largest reduction occurring in the thalamus, which contains 10 times fewer D 2 Rs than does the striatum (95) . PFC neurons express 4-7 times more D 1 Rs than D 2 Rs in schizophrenia (93) . The latter group showed that there is a high correlation between task and thalamic dopamine released, indicating extrastriatal dopamine involvement in normal cognition and neuropsychiatric disorders.
L-3,4-Dihydroxy-6-18 F-Fluorophenylalanine ( 18 F-FDOPA) Studies. Since its introduction by Garnett et al. (96, 97) , 18 F-FDOPA has been used to study presynaptic dopamine metabolism in neuropsychiatric disorders. It is taken up by presynaptic monoaminergic neurons and decarboxylated to 18 F-flourodopamine, which is taken up and stored in nerve terminal vesicles. Reith et al. (5) Neuroleptics can highlight changes in the expression of dopamine receptors in the basal ganglia and dopaminergic systems. Medication-free schizophrenia patients show reduced 18 F-FDOPA uptake in the ventral striatum and increased uptake in the posterior cingulate (99) .
Graphical Analysis
Compartmental analysis can be used when determining tracer binding kinetics (100) . It models tracer uptake by separating the effects of transport from those of receptor binding by creating linear plots and solving differential equations that represent the latter. The plot slope approximately equates to the distribution volume and plasma contribution and is related to the number of tracer binding sites. Model parameters are determined by fitting the models to the PET data collected using several assumptions and approaches. Graphical models can be created for both reversible and irreversible tracers. The models used to describe uptake and binding of PET tracers can consist of 2 or more compartments, with transfer constants describing the uptake and reversibility of the tracer (Fig. 4) . The models for reversible and irreversible tracers differ in that the final compartment of the model for irreversible tracers has transfer constants such that the binding of the tracer to the receptor or bound tissue (k 3 ) is nonzero and the dissociation from the specific binding (k 4 ) is zero, because irreversible tracers are trapped during scanning.
18 F-Fallypride Studies. Dopamine receptors in schizophrenia have been investigated using 18 F-fallypride. Mukherjee et al. (101) studied D 2 R and D 3 R distribution in healthy unmedicated, caffeine-free (for at least 4 h) volunteers using 18 F-fallypride PET and coregistered MR images. Images were corrected for subject motion by realignment of the dynamic PET datasets to a reference summed image (102). The PET data were then analyzed using graphical methods, with the cerebellum as a reference region because it has minimal specific binding to dopaminergic sites. Time-activity curves and a pixel-by-pixel parametric image of the distribution volume ratio using an ROI-based approach were created (103) . The highest concentration was found in the putamen, followed by (in descending order) the caudate, thalamus, amygdala, substriatal region, hippocampus equal to temporal cortex, and orbitofrontal cortex (lowest concentration). There was a greater than 10% decrease in 18 F-fallypride binding per decade, which is in line with previous studies (104, 105) and may result from progressive-free radical change, loss of proteins because of inefficient recycling, and cell death (Fig. 5) (106) .
15 O-Water Studies. Andreasen et al. (107) studied a group of patients with schizophrenia undergoing 15 O-H 2 O PET to examine putative cognitive deficits. The fraction of radioisotope in arterial plasma was fitted to a biexponential function and used to correct the plasma-measured input function for blood-borne metabolites. Two tasks were performed to determine whether brain abnormalities were intrinsic or secondary to task performance. In the first task (practical recall), the neural simulation would be equivalent to that of healthy volunteers, and in the second (novel recall) these would differ. PET showed the presence of a prefrontal-thalamic-cerebellar network that is activated in controls but dysfunctional in schizophrenia, suggesting cognitive dysmetria (the inability to receive and process information rapidly and effectively); patients have complex circuits that may display varying patterns of disruption depending on the task. 18 (110, 111) , which assumes there is an irreversible compartment. Also, Logan analysis is theoretically more stable during short scan times in dynamic studies, providing accurate quantification for dynamic 18 F-FDOPA data.
Patlak analysis was used with ROI analysis by McGowan et al. (68) to show increased presynaptic striatal 18 F-FDOPA uptake and decreased prefrontal cortical uptake in medicated schizophrenia patients. Studies on medicated patients elucidate the effects of medication on decarboxylase activity, which influences the rate of dopamine synthesis (112) . This regional dopamine dysfunction has previously been shown in unmedicated schizophrenia patients (49, 51) .
More recently, Howes et al. (113) used 18 F-FDOPA to investigate a putative association between striatal dopaminergic function, symptomatology, and neuropsychologic functioning using Patlak analysis. Patients with prodromal schizophrenia symptoms showed heightened striatal 18 F-FDOPA uptake, which gradually reached the level in those with schizophrenia. Increased striatal dopamine uptake positively correlated with severity of prodromal symptom and performance on neuropsychologic tasks.
PET IN IDENTIFICATION OF BRAIN REGIONS ASSOCIATED WITH COGNITIVE FUNCTIONING
Cognition is considered an extension of the clinical phenotype of the schizophrenia syndrome (23, 114) . Studying the relationship between specific brain abnormalities and cognitive functioning in schizophrenia can enable us to identify abnormal regions and neurocircuitry. Frith (115) modeled cognitive processes in schizophrenia using PET studies showing regional cerebral blood flow differences.
Brain metabolism and function are used to assess functional changes associated with the dopaminergic system. Cerebral blood blow is often used to index brain function. Increased motor function is associated with increased regional cerebral blood flow, mapped using a PET tracer specifically water-labeled with 15 O. PET allows detailed mapping of motor function or cognitive processes such as language, attention, memory, and emotion. Regions activated during specific tasks have increased radionuclide uptake. These images are quantified by drawing ROIs around activated regions and comparing psychiatric disorders and controls. Using 15 O-water PET, Crespo-Facorro et al. (116) investigated cognitive dysmetria in medicationfree schizophrenia patients and controls by examining verbal learning and recognition. During recall of well-learned word lists, schizophrenia patients did not show activation in cortical-cerebellar-thalamic-cortical circuitry.
Neuroleptics may lead to emotional changes in schizophrenia patients. Paradiso et al. (117) performed 15 O-water PET studies on patients who were antipsychotic-free for at least 3 wk. They were exposed to pleasant and unpleasant stimuli. They showed no activation in the PFC and decreased thalamic and cerebral blood flow, suggesting dysfunctional connectivity.
Hypofrontality is an abnormality in brain function in which there is reduced activation in the frontal (especially prefrontal) cortex. Weinberger et al. (118, 119) showed that patients were hypofrontal (independent of medication effects) during performance on the Wisconsin card sorting test (WCST), a measure of executive function and problemsolving ability that assesses prefrontal cortical functioning. Numerous resting-state studies in schizophrenia have shown hypofrontality, particularly in chronic schizophrenia (120) , and in psychomotor syndrome (121, 122) . Frontal activation is associated with cognitive performance. Fletcher et al. (123) used the California verbal learning test to show reduced frontal activation, and therefore impaired performance, during a high-processing load subtest. Similarly, some studies (124, 125) have reported that reduced frontal activation in schizophrenia during a working memory task (n-back task) occurs only when there is high memory load and impaired performance. These studies indicate the importance of task difficulty on frontal lobe activation in schizophrenia.
The dorsolateral PFC plays a role in resolving conflict between competing responses (126) . Reduced dopaminergic activity may contribute to impaired activity or function in schizophrenia. For instance, Weinberger et al. (119) showed a correlation between impaired prefrontal activation during the WCST and low cerebrospinal fluid homovanillic acid (a dopamine metabolite). Amphetamines (indirect dopaminergic agonists) can, at least to some extent, help reverse poor frontal activation to WCST (127) . Specific genes for schizophrenia also play a role, whereby those with slower dopamine catabolism (because of COMT variation) have a more efficient prefrontal response (39) . Recently, however, hypofrontality has been considered an inconsistent finding that varies with task and symptomatology (128) . Hypofrontality is present at rest and results in reduced activation of the frontal regions (129, 130) .
Several studies have investigated the association between the PFC and performance on executive functioning and attention tasks. Andreasen et al. (122) showed decreased prefrontal activation using SPECT in patients with predominantly negative symptoms with the Tower of London paradigm. Heckers et al. (131) identified changes in episodic memory in schizophrenia, suggesting that during these tasks patients have normal dorsolateral PFC functioning but reduced hippocampal activation. Christian et al. (132) reported a positive correlation between performance on a spatial attention task and dopamine release in the thalamus.
DISCUSSION
The dopamine hypothesis explains how an individual with neurodevelopmental deviance, or an isolated adolescent with bizarre ideas, transforms into an actively psychotic individual. Converging lines of evidence suggest dopamine dysregulation in schizophrenia (3, 60, 133) .
PET tracers used to identify brain abnormalities include 11 C PET, 15 O-water, 18 F-fallypride, and 18 F-FDOPA. Some tracers used in PET neuroimaging require radioactive isotopes of short half-lives, therefore requiring a cyclotron close by. Also, the radiation dose may restrict repeated scanning. Some studies used compartmental modeling to determine tracer binding kinetics. These studies show increased dopamine content and higher D 2 R density in schizophrenia.
PET has identified regions associated with cognitive functioning in schizophrenia. Earlier human PET studies focused on the relationship between dopamine neurotransmission and cognitive functioning while patients were in states of acute or florid illness. One such study showed a positive correlation between working memory and bloodbrain 18 F-FDOPA clearance in schizophrenia (69); heightened striatal 18 F-FDOPA use in patients also occurred (5, 6) .
PET allows the assessment of brain receptor binding and mapping of regional cerebral blood flow and glucose metabolism during cognitive activation. 15 O-water studies (116) showed a significant variation between patients with schizophrenia and healthy controls-variation that was not a consequence of the reduction in blood flow seen in schizophrenia but probably caused by a disruption in neural connectivity (i.e., dopamine dysregulation).
Some studies have investigated the effect of medication on tracer-receptor binding. Amphetaminelike drugs cause an increase in striatal dopamine in schizophrenia (70) . Antipsychotic medication increases D 2 R densities in schizophrenia (72) .
CONCLUSION
PET imaging provides substantial insights into the pathophysiology of schizophrenia. Although this imaging technique involves exposure to ionizing radiation and is expensive, compared with MRI, it is particularly valuable in understanding the neurobiological mechanisms underpinning schizophrenia. Future neuroimaging work should further elucidate the association between brain abnormalities, genetic underpinnings, and cognitive functioning in schizophrenia.
